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Hepatocellular carcinoma (HCC) is the fifth most com-
mon malignancy worldwide and the third most common
cause of cancer related deaths worldwide. We set out to
perform immune studies in HCC.
In a recent published mouse model of HCC, the hydro-
dynamic injection of two plasmids, pT3-EF5-hMET
(pMET) and pT3CAT led to prompt tumor growth. We
modified the pT3CAT plasmid with conventional PCR
cloning methods to create pCAT_LucOS, in which lucifer-
ase including T cell epitopes is expressed in addition to
the onogene.
Whereas co-delivery of pMET and pT3CAT in
C57BL/6 mice led to rapid tumor development, that
required euthanasia within 9 weeks, co-delivery of
pMET and pCAT_LucOS did not lead to any signs of
tumor burden over a course of 7 months. In contrast,
survival studies with immunocompromised Rag1KO
mice showed similar survival between mice that were
injected with the same plasmid combinations.
CAT gene expression was elevated over normal liver tis-
sue level in pMET and pT3CAT injected C57BL/6 mice
over the course of the 9 week experiment. In pMET and
pCAT_LucOS injected mice the CAT expression level was
elevated only in the first 2 weeks after the injection.
The tumor bearing pMET and pT3CAT injected mice
showed increased frequencies of CD11b+Gr-1+ MDSC
and CD11b+F4/80+ Macrophages and decreased frequen-
cies of CD4+ and CD8+ T cells in the liver. In pMET and
pCAT_LucOS injected mice an increase in CD8+ T cells
in the first two weeks was seen together with strong CD8
response against one of the tumor specific T cell epitopes.
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